Expression of TGF-β1 and its receptor genes (TβR I, TβR II, and TβR III-betaglycan) in peripheral blood leucocytes in patients with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome

International Journal of Molecular Medicine

Volumn 21, Issue 1, 2008, Pages 99-107

  Jachec, Wojciech ^a   Foremny, Ala ^a   Domal Kwiatkowska, Dorota ^a   Smolik, Slawomir ^a   Tomasik, Andrzej ^a   Mazurek, Urszula ^a   Wodniecki, Jan ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Eisenmenger's syndrome; Idiopathic pulmonary arterial hypertension; Transforming growth factor 1; T R I; T R II; T R III betaglycan

Indexed keywords

GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; BETAGLYCAN; PROTEIN SERINE THREONINE KINASE; PROTEOGLYCAN; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; EISENMENGER COMPLEX; ESSENTIAL HYPERTENSION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; LEUKOCYTE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; GENE EXPRESSION REGULATION; GENETICS; HEMODYNAMICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PULMONARY ARTERY;

ADOLESCENT; ADULT; AGED; CHILD; EISENMENGER COMPLEX; FEMALE; GENE EXPRESSION REGULATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LEUKOCYTES; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; PULMONARY ARTERY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 38949162570     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.21.1.99     Document Type: Article

References (64)

1. Palevsky HJ, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E and Fishman AP: Primary pulmonary hypertension. Vascular structure, morphometry and responsiveness to vasodilator agents. Circulation 80: 1207-1221, 1989.
2. Pietra GG, Edwards WD, Kay JM, et at: Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80: 1198-1206, 1989.
3. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF and Tuder RM: Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Am J Pathol 155: 411-419, 1999.
4. D'Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension. Results from a National Prospective Registry. Ann Intern Med 115: 343-349, 1991.
5. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M and Guerrero L: Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89: 1733-1744, 1994.
6. Rich S and Levy PS: Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. Am J Med 76: 573-578, 1984.
7. Loyd JE, Butler MG, Foroud TM, Cormeally PM, Phillips III JA and Newman JH: Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 152: 93-97, 1995.
8. Hood WB, Spencer H, Lass RW and Daley R: Primary pulmonary hypertension: Familial occurrence. Br Heart J 30: 336-343, 1968.
9. Elliott G, Alexander G, Leppert M, Yeates S and Kerber R: Coancestry in apparently sporadic primary pulmonary hypertension. Chest 108: 973-977, 1995.
10. Deng Z, Haghighi F, Helleby L, et al: Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Respir Crit Care Med 161: 1055-1059, 2000.
11. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC and Nygaard TG: Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q3l-q32. Circulation 95: 2603-2606, 1997.
12. Machado RD, Pauciulo MW, Fretwell N and the International PPH Consortium: A physical and transcript map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension. Genomics 68: 220-228, 2000.
13. The International PPH Consortium, Lane KB, Machado RD, Pauciulo MW, et al: Hetrozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nature Genet 26: 81-84, 2000.
14. Machado RD, Pauciulo MW, Thomson JR, et al: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68: 92-102, 2001.
15. Deng Z, Morse JH, Stager SL, et al: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Genet 67: 737-744, 2000.
16. Thomson JR, Machado RD, Pauciulo MW, et al: Sporadic primary pulmonary hypertension is associated with germline mutation of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet 37: 741-745, 2000.
17. Agrotis A, Samuel M, Prapas G and Bobik A: Vascular smooth muscle cells express multiple type I receptors for TGF-β, activin, and bone morphogenetic proteins. Biochim Biophys 219: 613-618, 1996.
18. Botney MD, Bahadori L and Gold LI: Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-β. Am J Pathol 144: 286-295, 1994.
19. Sankar S, Mahooti-Brooks N, Bensen L, McCarthy TL, Centrella M and Madri JA: Modulation of transforming growth factor-β receptor levels on microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 97: 1436-1446, 1996.
20. Massague J and Chen Y-G: Controlling TGF-β signaling. Genes Dev 14: 627-644, 2000.
21. Letamendia A, Lastres P, Botella LM, et al: Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 273: 33011-33019, 1998.
22. Wong SH, Hamel L, Chevalier S and Philip A: Endoglin expression on human microvascular endothelial cells. Association with betaglycan and formation of higher order complexes with TGF-β signalling receptors. Eur J Biochem 267: 5550-5560, 2000.
23. Kaname S and Ruoslahti E: Betaglycan has multiple binding sites for transforming growth factor-81. Biochem J 315: 815-820, 1996.
24. Takeda M, Otsuka F, Nakamura K, et al: Characterisation of the bone morphogenetic protein (BMP) system in human pulmonary arterial smooth muscle cells isolated from a sporadic case of primary pulmonary hypertension: Roles of BMP type IB receptor (activin receptor-like kinase-6) in the mitotic action. Endocrinology 145: 4344-4354, 2004.
25. West J, Fagan K, Steudel W, et al: Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94: 1109-1114, 2004.
26. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK and Trembath RC: Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins. Circulation 104: 790-795, 2001.
27. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC and Morrell NW: Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105: 1672-1678, 2002.
28. Zhang S, Fantozzi I, Tigno DD, et al: Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 285: L740-L754, 2003.
29. Galie N, Torbicki A, Barst R, et al: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 25: 2243-2278, 2004.
30. Geraci MW, Moore M, Gesell T, et al: Gene expression patterns in the lungs patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 88: 555-562, 2001.
31. Bull TM, Coldren CD, Moore M, et al: Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med 170: 911-919, 2004.
32. Lee S-D, Shroyer KR, Markham NE, Cool CD, Voelkel NF and Tuder RM: Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101: 927-934, 1998.
33. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al: Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438, 2001.
34. Mata-Greenwood E, Meyrick B, Steinhorn RH, Fineman JR and Black SM: Alterations in TGF-β1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 285: L209-L221, 2003.
35. Gao BH, Yao RX, Zhao ZG, Xie LW, Xiang RL, Hu XT and Wang ZM: Expression and pathological implication of transforming growth factor-beta1 mRNA and endothelin-1 mRNA in intraacinar pulmonary arterioles of congenital heart disease accompanied with pulmonary hypertension. Zhonghua Bing Li Xue Za Zhi 34: 159-162, 2005.
36. Botney MD, Parks WC, Crouch EC, Stenmark K and Mecham RP: Transforming growth factor-β1 is decreased in remodeling hypertensive bovine pulmonary arteries. J Clin Invest 89: 1629-1635, 1992.
37. Perkett EA, Lyons RM, Moses HL, Brigham KL and Meyrick B: Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension. J Clin Invest 86: 1459-1464, 1990.
38. Pepper MS, Vassalli J-D, Orci L and Montesano R: Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis. Science 204: 356-363, 1993.
39. Itoh F, Asao H, Sugamura K, Heldin C-H, ten Dijke P and Itoh S: Promoting bone morphogenctic protein signaling through negative regulation of inhibitory Smads. EMBO J 20: 4132-4142, 2001.
40. Galvin KM, Donovan MJ, Lynch CA, et al: A role for Smad6 in development and homeostasis of the cardiovascular system. Nat Genet 24: 171-174, 2000.
41. Afrakhte M, Moren A, Jossan S, et al: Induction of inhibitory Smad6 and Smad7 mRNA by TGF-13 family members. Biochem Biophys Res Commun 249: 505-511, 1998.
42. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M and Miyazono K: Smad6 inhibits signalling by the TGF-β superfamily. Nature 389: 622-626, 1997.
43. Nakao A, Afrakhte M, Moren A, et al: Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signalling. Nature 389: 631-635, 1997.
44. Yang X, Long L, Southwood M, et al: Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96: 1053-1063, 2005.
45. Kimura N, Matsuo R, Shibuya H, Nakashima K and Taga T: BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 275: 17647-17652, 2000.
46. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, et al: Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression. J Biol Chem 274: 27161-27167, 1999.
47. Panchenko MP, Williams MC, Brody JS and Yu Q: Type I receptor serine-threonine kinase preferentially expressed in pulmonary blood vessels. Am J Physiol 270: L547-L558, 1996.
48. Oh SP, Seki T, Goss KA, Imamura T, et al: Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97: 2626-2631, 2000.
49. Goumans M-J, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P and ten Dijke P: Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 21: 1743-1753, 2002.
50. Lu S-L, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K and Yuasa Y: HNPCC associated with germline mutation in the TGF-β type II receptor gene. Nat Genet 19: 17-18, 1998.
51. Sun L, Wu G, Willson JK, et al: Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269: 26449-26455, 1994.
52. Knaus PI, Lindemann D, DeCoteau JF, et al: A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 16: 3480-3489, 1996.
53. Myeroff LL, Parsons R, Kim SJ, et al: A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55: 5545-5547, 1995.
54. Villanueva A, Garcia C, Paules AB, et al: Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 17: 1969-1978, 1998.
55. Yeager ME, Halley GR, Golpon HA, Voelkel NF and Tuder RM: Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 88: e2-e11, 2001.
56. Richter A, Yeager ME, Zairnan A, Cool CD, Voelkel NF and Tuder RM: Impaired transforming growth factor-β signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 170: 1340-1348, 2004.
57. Morello JP, Plamondon J, Meyrick B, Hoover R and O'Connor-McCourt MD: Transforming growth factor-beta receptor expression on endothelial cells: heterogeneity of type III receptor expression. J Cell Physiol 165: 201-211, 1995.
58. Ji C, Chen Y, McCarthy TL and Centrella M: Cloning the promoter for transforming growth factor-β type III receptor. J Biol Chem 274: 30487-30494,1999.
59. Philip A, Hannah R and O'Connor-McCourt M: Ectodomain cleavage and shedding of the type III transforming growth factor-β receptor in lung membranes. Effect of temperature, ligand binding and membrane solubilization. Eur J Biochem 261: 618-628, 1999.
60. Eickelberg O, Centrella M, Reiss M, Kashgarian M and Wells RG: Betaglycan inhibits TGF-signaling by preventing type I - type II receptor complex formation. J Biol Chem 277: 823-829, 2002.
61. Sankar S, Mahooti-Brooks N, Centrella M, McCarthy TL and Madrid JA: Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor β2. J Biol Chem 270: 13567-13572, 1995.
62. Gilboa L, Nohe A, Geissendorfer T, Sebald W, Henis YI and Knaus P: Bone morphogenetic protein receptor complexes on the surface of live cells: A new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell 11: 1023-1035, 2000.
63. Nolmo T, Ishikawa T, Saito T, Hosokawa K, Noji S, Wolsing DH and Rosenbaum JS: Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heterometric complexes with bone morphogenetic protein type I receptors. J Biol Chem 270: 22522-22526, 1995.
64. Gilboa L, Wells RG, Lodish HF and Henis YI: Oligomeric structure of type I and type II transforming growth factor β receptors: Homodimers form in the ER and persist at the plasma membrane. J Cell Biol 140: 767-777, 1998.